Clinical trial · Interventional
Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer
Precision Chemotherapy Based on Organoid for Colorectal CancerPatient-Derived Tumor Organoid Drug Sensitivity for Colorectal Cancer: A Prospective, Multicentre，Randomized, Controlled Trial
NCT05832398CI-TRIAL-00067633unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate whether chemotherapy guided by patient-derived tumor organoid drug test can improve the outcomes of stage IV colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FOLFOX , FOLFIRI or FOLFOXIRI regimens | Drug | — | UNRESOLVED |
| FOLFOX or CapeOX regimens | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Organoid guided chemotherapy
- description
- Patients will receive sensitive chemotherapy in organoid drug test once every two weeks for 6 cycles as adjuvant chemotherapy
- interventionNames
- Drug: FOLFOX , FOLFIRI or FOLFOXIRI regimens
- type
- ACTIVE_COMPARATOR
- label
- FOLFOX regimen
- description
- Patients will receive FOLFOX regimen once every two weeks for 6 cycles as adjuvant chemotherapy
- interventionNames
- Drug: FOLFOX or CapeOX regimens
Primary outcomes (1)
- measure
- 1. Progression-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 18 and 70 * Histological confirmed colorectal cancer * Stage IV * American Society of Anesthesiologists (ASA) score I\~III * No contraindication for chemotherapy * No evidence of other malignant tumor Exclusion Criteria: * Refusing chemotherapy * Pregnant or breast-feeding women * Severe organ damage after chemotherapy, surgery or unable to continue to systemic chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.